Purchase Order 75N93024P01101
Award Date 9/9/24
Potential Completion Date 9/8/25
Potential Value $15K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Rockville, MD 20850, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract was awarded to Bioreliance Corporation, a foreign-owned, for-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $6,065,128.00, is a definitive contract with a cost-plus-fixed-fee pricing type. Bioreliance, through its Life Sciences Services Division, will provide a range of specialized testing services to support investigational new drug...
- This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Bioreliance Corporation for endotoxin and sterility testing services. The $16,051.00 firm fixed price contract does not have a set-aside designation, indicating Bioreliance's competitive standing in the field of pharmaceutical and biotechnology research and development. As a foreign-owned, for-profit organization,...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $14,561.00 firm fixed price purchase order contract to Bioreliance Corporation, a foreign-owned for-profit company, to provide endotoxin, sterility, and general safety testing services in support of investigational new drug applications. The contract includes isolator sterility testing using direct inoculation methods, LAL testing for...
- This federal contract award, with ID HHSN272201600262P, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Bioreliance Corporation, a foreign-owned, for-profit organization that specializes in providing critical testing services to the U.S. government. The $9,566.00 fixed-price contract is for endotoxin testing services, which are crucial for advancing health initiatives and drug development processes. Bioreliance, through its Life Sciences Services Division,...
- Bioreliance Corporation, a foreign-owned for-profit organization, was awarded a $34,978 firm-fixed-price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) to provide endotoxin, sterility, and general safety testing services in support of investigational new drug (IND) applications for NIAID's Pfs230D1-CRM197 and Pfs230D1-EPA malaria vaccine products. The contract, which does not have a set-aside designation, runs through August 31, 2024. Bioreliance has...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), an agency within the U.S. Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned, for-profit organization specializing in critical testing services for the pharmaceutical and biotechnology industries. The $4,930.00 firm fixed-price purchase order is for Bioreliance's cell bank storage and other related functions. This award is not designated as a...
- The Department of Health and Human Services National Institutes of Health (NIH) National Cancer Institute awarded a $80,848.00 Delivery Order contract to Bioreliance Corporation, a foreign-owned for-profit organization, for sterility testing services. The contract is for endotoxin, sterility, and general safety testing to support investigational new drug applications. Bioreliance has a history of providing these types of testing services to the NIH National Institute of Allergy and Infectious...
- This is a Firm Fixed Price Delivery Order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned for-profit organization. The contract, valued at $87,849.55, is for sterility testing services (STERILITY (510120GMP.BSV)) with a completion date of November 20, 2014. Bioreliance, through its Life Sciences Services Division, is a specialized provider of microbiological examination,...
- The National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, awarded a $91,832.29 firm fixed-price delivery order to Bioreliance Corporation, a foreign-owned for-profit organization. The contract, which has no set-aside designation, is for Bioreliance's Life Sciences Services division to provide a range of specialized testing services, including endotoxin, sterility, and general safety testing, in support of investigational new drug...
- The National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, awarded a $86,333.97 firm fixed price delivery order to Bioreliance Corporation, a foreign-owned, for-profit organization, for the provision of sterility testing services. This contract does not have a set-aside designation. Bioreliance, through its Life Sciences Services Division, is a key supplier of critical testing services to federal health agencies, including endotoxin,...